BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Japan's Kaneka Corporation acquires 96.8% of shares of Israeli medical equipment company EndoStream

January 9, 2025 | News

EndoStream is developing a device for the treatment of cerebral aneurysms called Ã¢â?¬Å?NautilusÃ¢â?¬Â•



Japanese firm Kaneka Corporation has acquired 96.8% of shares of EndoStream Medical, an Israeli medical equipment company. By combining Kaneka's manufacturing and ESM's technology, both companies will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus (*as seen in the image*) device for aneurysm treatment currently under development. Both companies jointly aim to achieve sales of over 20 billion yen by 2030.

ESM is a manufacturer of innovative technologies in the field of cerebrovascular diseases and is developing a device for the treatment of cerebral aneurysms called “Nautilus” that can treat aneurysms with wide openings in cerebral blood vessels, which has been awaited by neurovascular community for many years.

The device has a special structure that can be used in combination with an aneurysm embolisation coil to block blood flow to the aneurysm, facilitating treatment that would otherwise be difficult with existing devices.
The product received regulatory approval in Europe in November 2024, with plans for approval and launch in the United States in the spring of 2026 and in Japan one year later.

Kaneka is developing its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. In the growing field of cerebrovascular diseases, among others, Kaneka provides “i-ED COIL”, an embolisation coil that prevents damage to cerebral aneurysms that cause subarachnoid hemorrhage. Thus, the company is expanding its product portfolio for further growth. The Health Care Solution Unit, which includes these medical businesses, aims to achieve sales of 300 billion yen by 2030.